Clinical Director, Division of Cancer Genetics and Prevention
Senior Physician, Dana-Farber Cancer Institute
Assistant Professor of Medicine, Harvard Medical School
Huma Q. Rana, MD, MPH is the Clinical Director
of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer
Institute, and Assistant Professor of Medicine at Harvard Medical School. At
Dana-Farber and its affiliates and satellites, Dr. Rana oversees the medical
management and the clinical operations that provide care to individuals with
rare genetic susceptibilities to cancer.
In addition to her clinical work, Dr. Rana leads
multiple clinical research projects focused on developing cancer prevention and
screening for those with hereditary cancer risk, and novel approaches to
improving access to cancer genetics services.
Dr. Rana received her medical degree from the Rutgers
Robert Wood Johnson Medical School, completed her residencies in Internal
Medicine and Clinical Genetics at the Icahn School of Medicine at Mount Sinai,
and received her MPH from the Harvard T.H. Chan School of Public Health. She has been a member of the Dana-Farber
faculty since 2012.
Clinical Director, Division of Cancer Genetics and Prevention
Senior Physician, Dana-Farber Cancer Institute
Assistant Professor of Medicine, Harvard Medical School
Huma Q. Rana, MD, MPH is the Clinical Director
of the Division of Cancer Genetics and Prevention at Dana-Farber Cancer
Institute, and Assistant Professor of Medicine at Harvard Medical School. At
Dana-Farber and its affiliates and satellites, Dr. Rana oversees the medical
management and the clinical operations that provide care to individuals with
rare genetic susceptibilities to cancer.
In addition to her clinical work, Dr. Rana leads
multiple clinical research projects focused on developing cancer prevention and
screening for those with hereditary cancer risk, and novel approaches to
improving access to cancer genetics services.
Dr. Rana received her medical degree from the Rutgers
Robert Wood Johnson Medical School, completed her residencies in Internal
Medicine and Clinical Genetics at the Icahn School of Medicine at Mount Sinai,
and received her MPH from the Harvard T.H. Chan School of Public Health. She has been a member of the Dana-Farber
faculty since 2012.
Journal article
In individuals with classic Li Fraumeni Syndrome (LFS) due to a loss of function pathogenic germline variant in TP53, loss of p53 tumor suppressive function leads to a high risk of childhood cancers such as sarcomas, adrenal cortical carcinomas, brain tumors and leukemia. In adults with classic LFS, in addition to the classical malignancies, breast cancers and other cancers develop at earlier ages of onset compared to individuals without LFS. Increased genetic testing is identifying a higher...
Journal article
CONCLUSION: Rapid demonstrated high genetic testing uptake and effective integration into oncology workflows, enabling timely treatment decisions. Although the program optimized resource use and reduced barriers, disparities in testing remain. Future efforts should address these inequities and evaluate the long-term impact of genetic testing on patient outcomes.